|
A Phase I/II Clinical Study of FH-006 for Injection in Patients With Malignant Solid Tumors
RECRUITINGPhase 1/2Sponsored by Jiangsu HengRui Medicine Co., Ltd.
Actively Recruiting
PhasePhase 1/2
SponsorJiangsu HengRui Medicine Co., Ltd.
Started2025-09-23
Est. completion2027-02
Eligibility
Age18 Years – 75 Years
Healthy vol.Accepted
View on ClinicalTrials.gov →
NCT07136142
Summary
This study aims to evaluate the safety, tolerability, pharmacokinetics and immunogenicity of FH-006 in subjects with advanced malignant solid tumors, and determine the preliminary efficacy.
Eligibility
Age: 18 Years – 75 YearsHealthy volunteers accepted
Inclusion Criteria: 1. Subjects with ability to understand and voluntarily agree to participate by giving written informed consent for the study. 2. Patients with unresectable recurrent or metastatic solid tumors. 3. There is at least one lesion that could be measured. 4. An Eastern Cooperative Oncology Group (ECOG) performance status (PS) score of 0 or 1. 5. Adequate organ functions as defined. 6. Life expectancy ≥ 3 months. Exclusion Criteria: 1. Patients with known active central nervous system (CNS) metastases. 2. Subjects who had other malignancy in five years before the first dose. 3. Patients with tumor-related pain that can not be controlled as determined. 4. Patients with serious cardiovascular and cerebrovascular diseases. 5. Uncontrollable third-space effusion, such as pleural effusion, pericardial effusion or peritoneal effusion. 6. Patients with severe infections. 7. History of immunodeficiency. 8. History of autoimmune diseases. 9. Unresolved CTCAE Grade \>1 toxicity attributed to any prior anti-tumor therapy. 10. Active infection. 11. Pregnant or nursing women. 12. Known history of serious allergic reactions to the investigational product or its main ingredients.
Conditions2
CancerMalignant Solid Tumor
Interventions3
Related trials
- A Clinical Study of JS105 in Combination With Other Anti-tumor Therapies in Patients With Solid Tumors — Risen (Suzhou) Pharma Tech Co., Ltd.
- A Study of Paclitaxel Combined With Apatinib and Adebrelimab in Gastric/Gastroesophageal Junction Adenocarcinoma — The First Affiliated Hospital of Xiamen University
- A Study of SHR-A2102 Versus Investigator's Choice of Chemotherapy in Patients With Platinum-based Chemotherapy and PD-(L)1 Inhibitor Treatment Failed Recurrent or Metastatic Cervical Cancer — Suzhou Suncadia Biopharmaceuticals Co., Ltd.
- A Study of TQB2930 for Injection Monotherapy or Combination Therapy in Patients With Recurrent/Metastatic Breast Cancer — Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Clinical Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of LM-108 ± Penpulimab+Chemotherapy in Advanced Solid Tumors - Cohort C — Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Polymeric Micellar Paclitaxel for Metastatic Pancreatic Cancer — Shanghai Yizhong Pharmaceutical Co., Ltd.
- Pyrotinib Plus Trastuzumab and Chemotherapy for HER2-Positive Early Breast Cancer — Hebei Medical University Fourth Hospital
- A Clinical Trial of SHR-A1811 in the Treatment of Triple-negative Breast Cancer — Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
Actively Recruiting
PhasePhase 1/2
SponsorJiangsu HengRui Medicine Co., Ltd.
Started2025-09-23
Est. completion2027-02
Eligibility
Age18 Years – 75 Years
Healthy vol.Accepted
View on ClinicalTrials.gov →
NCT07136142